1. Janz TA, Neskey DM, Nguyen SA, Lentsch EJ.
World J Otorhinolaryngol Head Neck Surg. World J
Ootorhinolaryngol Head Neck Surg 2019;5(01):34-
40.
2. Nagaiah G, Hossain A, Mooney CJ ,Parmentier J,
Remick SC. Anaplastic thyroid cancer: a review of
epidemiology, pathogenesis, and treatment. J Oncol.
2011;2011(1):542358.
3. Smallridge R, Copland J. Anaplastic thyroid
carcinoma: pathogenesis and emerging therapies. Clin
Oncol. 2010;22(6):486-97.
4. Dijkstra B, Prichard R, Lee A, Kelly L, Smyth P,
Crotty T, et al. Changing patterns of thyroid
carcinoma. Ir J Med Sci. 2007;176:87-90.
5. Ranganath R, Shah MA, Shah AR. Anaplastic thyroid
cancer. Curr Opin Endocrinol Diabetes Obes.
2015;22(5):387-91.
6. Mazeh H, Benavidez J, Poehls JL, Youngwirth L,
Chen H, Sippel RS. In patients with thyroid cancer of
follicular cell origin, a family history of nonmedullary
thyroid cancer in one first-degree relative is associated
with more aggressive disease. Thyroid. 2012;22(1):3-
8.
7. Hamidi S, Maniakas A. Recent advances in anaplastic
thyroid cancer management. Curr Opin Endocrinol
Diabetes Obes. 2023;30(5):259-64.
8. Siegel RL, Miller KD, Wagle NS, Jemal A. Cancer
statistics, 2023. CA Cancer J Clin. 2023;73(1):17-48.
9. Loscalzo J, Fauci AS, Kasper DL, Hauser SL, Longo
DL, Jameson JL. Harrison's principles of internal
medicine. (No Title). 2022.
10. Xu T ,Zhu C, Chen J, Song F, Ren X, Wang S, et al.
ISG15 and ISGylation modulates cancer stem cell-like
characteristics in promoting tumor growth of
anaplastic thyroid carcinoma. J Exp Clin Cancer Res.
2023;42(1):182.
11. Subbiah V ,Kreitman RJ, Wainberg ZA, Cho JY,
Schellens JH, Soria JC, et al. Dabrafenib and
trametinib treatment in patients with locally advanced
or metastatic BRAF V600–mutant anaplastic thyroid
cancer. J Clin Oncol. 2018;36(1):7-13.
12. Onda M, Emi M, Yoshida A, Miyamoto S, Akaishi
J, Asaka S, et al. Comprehensive gene expression
profiling of anaplastic thyroid cancers with cDNA
microarray of 25 344 genes. Endocr Relat Cancer.
2004;11(4):843-54.
13. Guo Y, Cen K, Chen Q, Dai Y, Mai Y, Hong K .
Identification and validation of a novel senescencerelated biomarker for thyroid cancer to predict the
prognosis and immunotherapy. Front Immunol.
2023;14:1128390.
14. Glaviano A, Foo AS, Lam HY, Yap KC, Jacot W,
Jones RH, et al. PI3K/AKT/mTOR signaling
transduction pathway and targeted therapies in cancer.
Mol Cancer. 2023;22(1):138.
15. He Y, Sun MM, Zhang GG, Yang J, Chen KS, Xu
WW, et al. Targeting PI3K/Akt signal transduction for
cancer therapy. Signal Transduct Target Ther.
2021;6(1):425.
16. Zhong Y, Yu F, Yang L, Wang Y, Liu L, Jia C, et al.
HOXD9/miR-451a/PSMB8 axis is implicated in the
regulation of cell proliferation and metastasis via
PI3K/AKT signaling pathway in human anaplastic
thyroid carcinoma. J Transl Med. 2023;21(1):817.
17. Nixon BG, Kuo F, Ji L, Liu M, Capistrano K, Do M,
et al. Tumor-associated macrophages expressing the
transcription factor IRF8 promote T cell exhaustion in
cancer. Immunity. 2022;55(11):2044-58. e5.
18. Pozniak J ,Pedri D, Landeloos E, Van Herck Y,
Antoranz A, Vanwynsberghe L, et al. A TCF4-
dependent gene regulatory network confers resistance
to immunotherapy in melanoma. Cell.
2024;187(1):166-83. e25.
19. Zhou F, Gao H, Shang L, Li J, Zhang M, Wang S, et
al. Oridonin promotes endoplasmic reticulum stress
via TP53-repressed TCF4 transactivation in colorectal
cancer. J Exp Clin Cancer Res. 2023;42(1):150.
20. Zhou J, Mo J, Tan C, Xie F, Liang J, Huang W.
JUND promotes tumorigenesis via specifically
binding on enhancers of multiple oncogenes in
cervical cancer. Onco Targets Ther. 2023:347-57.
21. Peng Y, Chen Y, Chen S, Wang J, Jiang C, Hou W,
et al. JUND-dependent up-regulation of HMOX1 is
associated with cisplatin resistance in muscle-invasive
bladder cancer. J Biochem. 2020;168(1):73-82.
مجله علوم پزشکی پارس